A total of 732 prospectively recruited German patients with metastatic renal cell carcinoma were classified as either "trial-eligible" or "trial-ineligible" in accordance with the common exclusion criteria for clinical trials. The "trial-ineligible" patients had shorter progression-free and overall survival compared with the "trial-eligible" patients, whose outcomes were comparable with those from clinical trials. Physicians should be aware of these differences when discussing the treatment options and outcome expectations with patients. Introduction: Because "real-life" patients often do not meet the strict eligibility criteria of clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal cell carcinoma (mRCC) in routine practice and compared the survival of "trial-ineligible" and potentially "trial-eligible" patients. Patients and Methods: The present prospective, multicenter German cohort study is recruiting patients from 110 oncology/urology outpatient centers and hospitals at initiation of systemic first-line treatment. The demographic, clinical, treatment, and survival data were collected. We defined patients as "trial-ineligible" when ! 1 exclusion criterion (Karnofsky performance status < 80%, hemoglobin less than the lower limit of normal, noneclear cell carcinoma histology) was documented. Otherwise, the patients were considered "trial-eligible". Results: Of 732 patients included, 57% were classified as "trial-ineligible". Overall, the median first-line progression-free survival (PFS) was 7.9 months (95% confidence interval [CI], 6.9-8.9 months). The median first-line PFS of "trial-eligible" and "trial-ineligible" patients was 11.0 months (95% CI, 9.6-13.1 months) and 5.3 months (95% CI, 4.6-6.5 months), respectively. The median OS of the "trial-eligible" and "trialineligible" patients was 26.0 months (95% CI, 22.1-29.7 months) and 12.6 months (95% CI, 10.6-15.8 months), respectively. Conclusion: Our data suggest that patients in routine practice differ from patients treated in clinical trials and that almost 60% of mRCC patients in German routine practice would be ineligible for participation in clinical trials. While their first-line PFS and OS were shorter than those of "trial-eligible" patients, the PFS and OS of "trial-eligible" patients were comparable with the results from clinical trials. Physicians should be aware of these differences when discussing treatment options and outcome expectations with patients.
Introduction
Renal cell carcinoma (RCC) accounts for > 90% of renal malignancies, with clear cell carcinoma the most common subtype (70%). 1 Every year, RCC is diagnosed in approximately 15,500 patients in Germany and advanced or metastatic RCC (mRCC) is diagnosed in about 40%. 2 The development of novel agents targeting signal transduction and angiogenesis pathways improved the outcomes of patients with mRCC. [3] [4] [5] [6] Sorafenib and sunitinib were the first approved targeted agents for mRCC, followed by temsirolimus, everolimus, bevacizumab, pazopanib, axitinib, 7 and, most recently, nivolumab. 8 The approval of these agents is based on results from controlled clinical registration trials with strict criteria for trial eligibility to ensure high internal validity and patient population homogeneity. However, the pertinent question is whether mRCC patients in clinical trials are representative of the real-life population for mRCC. 9 Patients treated in routine practice often do not meet the stringent criteria of clinical trials, especially those patients with lower performance status and impairing comorbidities. Hence, these patients are often classified as trial ineligible, and most probably experience inferior outcomes. This was shown by a recent study which reported that about one third of patients treated for mRCC with first-line vascular endothelial growth factor (VEGF)targeted therapy in 19 international cancer centers were classified as "trial-ineligible" and had inferior outcomes. 10 The German clinical registry on RCC (RCC Registry) gives insights into the characteristics and treatments of patients with mRCC receiving any systemic first-line treatment in German routine practice and permits investigations of their outcomes.
The objective of the present work was to assess the trial eligibility of patients in routine care in Germany according to the presence of common exclusion criteria and to compare the overall survival (OS) and progression-free survival (PFS) of "trial-ineligible" patients with potentially "trial-eligible" patients.
Patients and Methods

Data Source
The study cohort was obtained from the RCC Registry, which was started in December 2007. The RCC Registry is an ongoing, prospective, open, longitudinal, multicenter cohort study conducted by a network of > 280 office-or hospital-based medical oncologists and uro-oncologists located at 100 sites in Germany. A total of 1500 patients are intended to be recruited by the end of 2016. Patients aged ! 18 years with histologically confirmed mRCC will be included if they have provided written informed consent not > 4 weeks after the start of any systemic first-line treatment. For the first 1000 patients, the maximum difference between the start of firstline treatment and enrollment was 1 year, to allow the analysis of higher line treatment reality within the first years of the project. For the outcome analyses, the patients who provided written informed consent > 6 weeks after the start of treatment were excluded to avoid overestimation of the outcomes data (lead-time bias). Study sites are encouraged to enroll patients consecutively to ensure unselected recruitment. The patients are treated according to physician discretion.
At the time of enrollment, data on patient sociodemographic data, tumor characteristics, clinical parameters, concomitant diseases, and previous treatments are documented. Comorbidity is collected using the Charlson comorbidity index. 11 Additional comorbidities can be recorded as free text. The presence of prognostic factors according to the Memorial Sloan Kettering Cancer Center (MSKCC) 12 are documented at the start of each treatment line, including low (<80%) Karnofsky performance status (KPS), Survival of Clinical Trial vs. Routine mRCC Patients elevated lactate dehydrogenase level (>1.5 times the upper limit of normal), low hemoglobin (Hb) level (less than the lower limit of normal), elevated corrected calcium (greater than upper limit of normal), and the absence of previous nephrectomy. Using these factors, the patient's individual prognostic risk score is calculated (low risk, 0 risk factor; intermediate risk, 1-2 risk factors; high risk, 3-5 risk factors). During therapy, all systemic antineoplastic treatments (substance, dose, dose modifications, and duration) and radiotherapy regimens and/or surgeries are documented.
The treatment outcome parameters, including the dates of progression and date of death by any cause, are recorded. All data, including data on mortality, are collected from the patients' medical files and transferred to a secure web-based electronic case report form by physicians or trained study nurses. The data are updated after any change in treatment or at least every 3 months. Patients are followed up for a maximum of 3 years or until death, loss to followup, or withdrawal of consent. Automated plausibility and completeness checks with subsequently generated queries by the 
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Cohort Definition
A total of 1142 patients with mRCC had been recruited by 114 study sites until May 15, 2014. For 1111 of these patients, the baseline data and at least the start of first-line treatment were documented. Of these patients, 732 patients had provided written informed consent no longer than 6 weeks after the beginning of first-line treatment and were included in the present analysis ( Figure 1 ). This restriction on patients starting treatment not long before consent is crucial to avoid an overestimation of outcomes data such as OS. The cutoff date for the outcome data of patients included in the present analysis was May 15, 2015.
Definition of Trial Ineligibility and Eligibility
The trial eligibility and ineligibility of patients included in the present analysis was defined according to the common exclusion criteria found in phase III clinical trials [13] [14] [15] [16] and explicitly captured by the RCC Registry. Patients were classified as "trial-eligible" when !1 of the following criteria had been documented: KPS < 80%, Hb less than the lower limit of normal, and/or noneclear cell carcinoma histology. When none of these 3 criteria was fulfilled, patients were defined as potentially "trial-eligible".
If patients had data missing for some of these criteria, they were still classified as "trial-ineligible" if they had met ! 1 exclusion criterion. If patients had data missing for ! 1 exclusion criterion but were potentially eligible for all other criteria, they were considered "trial-eligible" to provide the most conservative estimate of trial eligibility.
Statistical Analysis
All analyses were performed using STATISTICA, version 10.0 (StatSoft, Inc), and SAS, version 9.4 (SAS Institute). The time to events was analyzed using Kaplan-Meier estimates. First-line PFS was defined as the interval between the first administration of any systemic treatment and the date of progression or death before the start of second-line treatment. Second-line PFS was defined as the interval between the beginning of systemic second-line treatment and the date of progression or death before the start of third-line treatment. OS was defined as the interval from the start of first-line treatment until death from any cause. Patients without progression, alive, or lost to follow-up were censored at the last contact or last documentation date. The log-rank test was used to compare PFS and OS between the "trial-ineligible" and "trial-eligible" patients. P values are reported in an exploratory manner without adjustments for multiplicity.
Results
Patient Characteristics
The patient characteristics and treatment of the 732 patients included in the present analysis are listed in Table 1 . Of the 732 patients, 57% were classified as "trial-ineligible" and 43% as "trialeligible" (Figure 1 ). Approximately 70% of patients were male, and the mean age was 68.0 AE 10.0 years at the start of first-line treatment (Table 1) . At the start of first-line treatment in both patient groups, ! 1 documented comorbidity was reported for about 80% of patients.
Of the patients considered "trial-ineligible", 7% had met all 3 exclusion criteria. Although 30% of the "trial-ineligible" patients had met 2 exclusion criteria, most were "trial-ineligible" because of 1 criterion (63%; all data on file). The most common reason for trial ineligibility was a lower Hb level (71%). The patients in the "trial-ineligible" group had a poorer prognosis than that of the "trial-eligible" patients according to the MSKCC risk score. Only about 10% of "trial-ineligible" patients were classified as having low risk at the start of first-line treatment compared with approximately 60% of "trial-eligible" patients.
Systemic Treatment
The duration of first-line treatment was shorter for the "trialineligible" than for the "trial-eligible" patients. The corresponding median treatment duration was 3.4 and 6.6 months. Overall, most patients (68%) were treated with tyrosine kinase inhibitors (TKIs) as first-line treatment ( Table 1) . The "trial-eligible" patients received TKIs slightly more often than did the "trial-ineligible" patients (74% vs. 64%). The latter were treated more than twice as frequently with mammalian target of rapamycin (mTOR) inhibitors (20% vs. 9%; Table 1 ). About one half of all patients included in the present analysis received second-line treatment.
Patient Outcomes
The median first-line PFS of the "trial-eligible" patients was > 2 times longer than that of the "trial-ineligible" patients (11.0 months; 95% CI, 9.6-13.1 months; and 5.3 months; 95% CI, 4.6-6.5 months, respectively; P < .0001; Table 2 , Figure 2 ). The median PFS with second-line treatment did not differ between the 2 groups ("trial-ineligible", 4.0 months; 95% CI, 3.1-5.0 months; "trial-eligible", 4.9 months; 95% CI, 4.0-6.1 months; Table 2 ). At the time of this analysis, 67% of the "trial-ineligible" patients and 56% of the "trial-eligible" patients had died. The median OS of the "trial-eligible" patients was approximately 2 times longer than that of the "trial-ineligible" patients (26.0 months; 95% CI, 22.1-29.7 months; and 12.6 months, 95% CI, 10.6-15.8, respectively; P < .0001; Table 2, Figure 3 ).
Similar results were obtained when patients treated with first-line mTOR inhibitors were excluded. The median OS for the "trialeligible" patients was 26.1 months (95% CI, 22.4-30.4 months) and was 15.9 months (95% CI, 12.3-18.3 months) for the "trialineligible" patients. The median PFS with first-line treatment was 11.1 months (95% CI, 9.7-13.9 months) for "trial-eligible" patients compared with 6.7 months (95% CI, 5.3-7.9 months) for "trialineligible" patients. The median PFS with second-line treatment was 4.9 months (95% CI, 4.0-6.1 months) for "trial-eligible" patients compared with 4.2 months (95% CI, 3.2-5.2 months) for the "trial-ineligible" patients.
The median OS for the 150 "trial-ineligible" patients with noneclear cell histology (11.4 months; 95% CI, 8.0-16.8 months) was slightly, but not significantly, shorter than that for the 237 "trial-ineligible" patients with clear cell histology (13.4 months; 95% CI, 10.6-17.9 months).
Discussion
Debate has ensued for some time regarding whether "real-life" patients experience inferior OS and shorter treatment durations compared with the results reported from clinical trials. The differences were mostly explained by multiple reasons, including higher comorbidity or worse performance status of the real-life patients. The analyses of factors leading to trial participation (or exclusion) could represent a reasonable method to explain the substantial differences between the outcomes data derived from randomized clinical trials and those reported from routine practice.
Our prospective real-life data suggest that almost 60% of mRCC patients in German routine care would be ineligible for participation in clinical trials, because they would meet common exclusion criteria (KPS < 80%, Hb less than the lower limit of normal, and noneclear cell carcinoma histology). As predicted, their first-line PFS and OS were significantly inferior compared with those of the "trial-eligible" patients. In contrast, patients without these factors had outcomes comparable to the published data from clinical trials.
The results of the present study were limited by the observational design. Because of possible differences other than the ones described between the groups of patients compared ("trial-ineligible" and "trial-eligible"), causal relations can not be drawn. Trial eligibility and ineligibility were defined using 3 exclusion criteria frequently defined in phase III clinical trials. The proportion of "trialineligible" patients might have been underestimated, because usually additional exclusion criteria are applied in clinical trials. However, these could not be included in our definitions of trial eligibility and ineligibility, mainly because they had not been collected for all patients in the RCC Registry. Also, several patients had missing data for some of the exclusion criteria; thus, our algorithm to manage missing data and determine each patient's 
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A substantial number of patients classified as "trial-ineligible" (35%) was also reported from 19 international cancer centers for mRCC patients treated with first-line VEGF therapy, with 65% of patients deemed "trial-eligible". 10 This difference might have been due to various reasons such as differing treatments, patient characteristics, and definitions of trial eligibility and ineligibility. The study by Heng et al 10 was restricted to mRCC patients undergoing VEGF-targeted therapy. In contrast, we included patients treated with any type of systemic therapy, including patients with a poorer prognosis receiving mTOR-targeted therapy. Differences were also present in the sites of recruitment. The group of Heng et al 10 recruited patients from international referral cancer centers worldwide, but the RCC Registry recruits patients from oncology and urology outpatient centers and (university) hospitals within the German healthcare system. Also, the median age of our population was about 10 years older than the age of those included in the study by Heng et al, 10 which might partially explain the greater proportion of "trial-ineligible" patients in our analysis. Increasing age is often associated with a lower KPS, one of the exclusion criteria determining eligibility or the lack of eligibility. The difference in age was also apparent between the entire population of the RCC Registry (median age, approximately 70 years) and the patients included in large clinical trials, with a median age of 62, 17 59, 14 or 61 years. 15 Our data showed that "trial-ineligible" patients had inferior outcomes and poorer prognostic risk scores compared with the "trial-eligible" patients. The median first-line PFS and OS of the "trial-ineligible" patients were 5.3 months and 12.6 months, respectively, approximately 2 times lower than those of patients potentially fulfilling trial eligibility. This effect was independent of the type of first-line treatment, with comparable results obtained when the analyses were restricted to patients not receiving the mTOR-targeted therapy usually prescribed to patients with poorer prognosis.
Similar findings of inferior outcomes for "trial-ineligible" patients were also reported for mRCC patients receiving first-line VEGFtargeted therapy. 10 For the "trial-ineligible" and "trial-eligible" patients, the median first-line PFS was 5.0 and 8.6 months and the median OS was 12.5 and 28.4 months, respectively. 10 These results most likely represent a general observation of patients with malignancies. In the Netherlands Cancer Registry, patients with stage IV colorectal cancer not fulfilling the criteria for trial eligibility had worse OS than that of eligible patients (9.3 vs. 15.7 months). 18 In contrast to the study by Heng et al, 10 which showed a shorter median second-line PFS for "trial-ineligible" patients compared with "trial-eligible" patients, in our analysis, the median PFS of second-line treatment did not differ substantially between the "trialineligible" and "trial-eligible" patients. This difference might have resulted from differences in later line treatment with targeted agents.
All 3 factors used in our study to determine patient eligibility are known prognostic factors for OS. A low KPS and the presence of anemia are included in the MSKCC prognostic score 12 and in the prognostic score reported by Heng et al. 19 In addition, it is known that patients with noneclear cell carcinoma histology have inferior survival compared with patients with clear cell histology. 20 Thus, the common exclusion criteria used in clinical trials are, in fact, prognostic factors, and the patients excluded from trials are those with an unfavorable prognosis. Our observation that patients with these factors are very common in routine practice highlights that the patient population treated in routine practice differs markedly from the population selected for clinical trials. Outcome data from clinical trials should therefore not be transferred to the entire patient population but only to those patients fulfilling the inclusion criteria.
For the "trial-eligible" patients included in our analysis, the median first-line PFS of 11.0 months and median OS of 26.0 months were similar to the survival times reported in phase III clinical trials, with a median first-line PFS of 5.5 to 11.0 months 14, 17, 21 and median OS of 17.8 to 26.4 months. 13, 15, 17, 22, 23 
Conclusion
Our data suggest that almost 60% of patients with mRCC in German routine practice would be ineligible for participation in a randomized clinical trial. Their first-line PFS and OS were inferior to those of "trial-eligible" routine patients, although those of "trialeligible" patients were comparable to those of clinical trial patients. This finding highlights that the patient population selected for clinical trials is not representative in terms of prognostic factors for the general patient population treated in routine practice. Physicians should be aware of these differences when discussing treatment options, guideline adherence, and outcomes expectations with individual patients.
Clinical Practice Points
We found that 57% of German mRCC patients would be ineligible for participation in clinical trials. Their first-line PFS and OS were shorter than those of "trialeligible" patients. The PFS and OS of the "trial-eligible" patients were comparable with the clinical trial data. Thus, the outcome expectations should be adjusted for real-life patients ineligible for clinical trials.
